Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neuromyelitis Optica × 90 days × Clear all
NCT06680037 2026-05-18

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

TG Therapeutics, Inc.

Phase 1 Recruiting
100 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔